Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Promedica Flower Hospital
125
mi
from 43215
Sylvania, OH
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Promedica Flower Hospital
125
mi
from 43215
Sylvania, OH
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University Hospitals Portage Medical Center
125
mi
from 43215
Ravenna, OH
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University Hospitals Portage Medical Center
125
mi
from 43215
Ravenna, OH
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Ascension Providence Hospitals - Novi
175
mi
from 43215
Novi, MI
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Ascension Providence Hospitals - Novi
175
mi
from 43215
Novi, MI
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Ascension Providence Hospitals - Southfield
173
mi
from 43215
Southfield, MI
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Ascension Providence Hospitals - Southfield
173
mi
from 43215
Southfield, MI
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Atrium Health Union/LCI-Monroe
369
mi
from 43215
Monroe, NC
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Atrium Health Union/LCI-Monroe
369
mi
from 43215
Monroe, NC
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
63
mi
from 43215
Dayton, OH
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital South
394
mi
from 43215
Saint Louis, MO
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital South
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Aurora Bay Area Medical Group-Marinette
425
mi
from 43215
Marinette, WI
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Aurora Bay Area Medical Group-Marinette
425
mi
from 43215
Marinette, WI
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
427
mi
from 43215
Oconto Falls, WI
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
427
mi
from 43215
Oconto Falls, WI
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Fort Apache
1756
mi
from 43215
Las Vegas, NV
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Fort Apache
1756
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Atrium Health Pineville/LCI-Pineville
348
mi
from 43215
Charlotte, NC
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Atrium Health Pineville/LCI-Pineville
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Marshfield
488
mi
from 43215
Marshfield, WI
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Marshfield
488
mi
from 43215
Marshfield, WI
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
UM Upper Chesapeake Medical Center
355
mi
from 43215
Bel Air, MD
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
UM Upper Chesapeake Medical Center
355
mi
from 43215
Bel Air, MD
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Atrium Health Cabarrus/LCI-Concord
341
mi
from 43215
Concord, NC
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Atrium Health Cabarrus/LCI-Concord
341
mi
from 43215
Concord, NC
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Rice Lake
584
mi
from 43215
Rice Lake, WI
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Rice Lake
584
mi
from 43215
Rice Lake, WI
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
481
mi
from 43215
New York, NY
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Center at Indian Path Community Hospital
237
mi
from 43215
Kingsport, TN
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Center at Indian Path Community Hospital
237
mi
from 43215
Kingsport, TN
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
243
mi
from 43215
Saginaw, MI
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
243
mi
from 43215
Saginaw, MI
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
146
mi
from 43215
Mentor, OH
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
146
mi
from 43215
Mentor, OH
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Southwest General Hospital
115
mi
from 43215
Middleburg Heights, OH
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Southwest General Hospital
115
mi
from 43215
Middleburg Heights, OH
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Firelands Regional Medical Center
103
mi
from 43215
Sandusky, OH
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Firelands Regional Medical Center
103
mi
from 43215
Sandusky, OH
Click here to add this to my saved trials
Oral Zinc for the Treatment of Acute Diarrhea in US Children
A Double Blind Randomized Placebo Controlled Trial of Oral Zinc for Children With Acute Diarrhea in a Developed Nation.
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
641
mi
from 43215
Boston, MA
Oral Zinc for the Treatment of Acute Diarrhea in US Children
A Double Blind Randomized Placebo Controlled Trial of Oral Zinc for Children With Acute Diarrhea in a Developed Nation.
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
641
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Status: Enrolling
Updated:  12/31/1969
Grady Infectious Diseases Clinic (Ponce Center)
434
mi
from 43215
Atlanta, GA
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Status: Enrolling
Updated: 12/31/1969
Grady Infectious Diseases Clinic (Ponce Center)
434
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2058
mi
from 43215
Redding, CA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2058
mi
from 43215
Redding, CA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
539
mi
from 43215
Bristol, CT
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
539
mi
from 43215
Bristol, CT
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
503
mi
from 43215
Stamford, CT
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
503
mi
from 43215
Stamford, CT
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
830
mi
from 43215
Clearwater, FL
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
830
mi
from 43215
Clearwater, FL
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
995
mi
from 43215
Coral Gables, FL
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
995
mi
from 43215
Coral Gables, FL
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
757
mi
from 43215
Port Orange, FL
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
757
mi
from 43215
Port Orange, FL
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
842
mi
from 43215
Saint Petersburg, FL
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
842
mi
from 43215
Saint Petersburg, FL
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1508
mi
from 43215
Idaho Falls, ID
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1508
mi
from 43215
Idaho Falls, ID
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
779
mi
from 43215
Newton, KA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
779
mi
from 43215
Newton, KA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
642
mi
from 43215
Brockton, MA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
642
mi
from 43215
Brockton, MA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
181
mi
from 43215
Troy, MI
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
181
mi
from 43215
Troy, MI
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
475
mi
from 43215
Neptune, NJ
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
475
mi
from 43215
Neptune, NJ
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
398
mi
from 43215
Binghamton, NY
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
398
mi
from 43215
Binghamton, NY
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
393
mi
from 43215
Endwell, NY
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
393
mi
from 43215
Endwell, NY
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
369
mi
from 43215
Cary, NC
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
369
mi
from 43215
Cary, NC
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
304
mi
from 43215
Hickory, NC
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
304
mi
from 43215
Hickory, NC
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
65
mi
from 43215
Centerville, OH
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
65
mi
from 43215
Centerville, OH
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
174
mi
from 43215
Uniontown, PA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
174
mi
from 43215
Uniontown, PA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
524
mi
from 43215
Mount Pleasant, SC
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
524
mi
from 43215
Mount Pleasant, SC
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
239
mi
from 43215
Bristol, TN
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
239
mi
from 43215
Bristol, TN
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
388
mi
from 43215
Williamsburg, VA
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
388
mi
from 43215
Williamsburg, VA
Click here to add this to my saved trials